GSA Capital Partners LLP Buys New Position in Annexon, Inc. $ANNX

GSA Capital Partners LLP purchased a new position in shares of Annexon, Inc. (NASDAQ:ANNX) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 104,378 shares of the company’s stock, valued at approximately $596,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. CIBC Bancorp USA Inc. bought a new position in Annexon during the 3rd quarter valued at $31,000. Engineers Gate Manager LP bought a new stake in shares of Annexon in the 2nd quarter worth $32,000. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Annexon by 65.6% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,033 shares of the company’s stock worth $35,000 after acquiring an additional 2,785 shares in the last quarter. Landscape Capital Management L.L.C. purchased a new stake in shares of Annexon in the fourth quarter valued at about $50,000. Finally, Mercer Global Advisors Inc. ADV purchased a new stake in shares of Annexon in the fourth quarter valued at about $52,000.

Annexon Price Performance

NASDAQ ANNX opened at $5.18 on Friday. The business’s fifty day moving average is $5.38 and its 200-day moving average is $5.47. The stock has a market capitalization of $982.02 million, a price-to-earnings ratio of -4.47 and a beta of 1.18. Annexon, Inc. has a one year low of $2.03 and a one year high of $7.18.

Annexon (NASDAQ:ANNX) last posted its quarterly earnings results on Wednesday, August 12th. The company reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.24) by ($0.04). Research analysts expect that Annexon, Inc. will post -1.01 EPS for the current fiscal year.

Insider Buying and Selling

In related news, Director Muneer A. Satter bought 613,497 shares of the company’s stock in a transaction on Thursday, May 28th. The shares were purchased at an average cost of $5.41 per share, for a total transaction of $3,319,018.77. Following the completion of the purchase, the director directly owned 10,342,134 shares in the company, valued at $55,950,944.94. The trade was a 6.31% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Corporate insiders own 10.31% of the company’s stock.

Analyst Ratings Changes

Several research analysts recently weighed in on ANNX shares. Citizens Jmp upgraded shares of Annexon from an “underperform” rating to a “market perform” rating in a report on Thursday, August 13th. HC Wainwright reiterated a “buy” rating and issued a $14.00 price objective on shares of Annexon in a research note on Monday, July 20th. Wall Street Zen cut shares of Annexon from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 15th. The Goldman Sachs Group started coverage on Annexon in a research note on Tuesday, May 12th. They issued a “neutral” rating and a $7.00 target price on the stock. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Annexon in a report on Friday, July 17th. Five equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $15.33.

Annexon Company Profile

Annexon Inc is a clinical-stage biotechnology company focused on the discovery and development of complement-targeted therapies for patients with neurodegenerative and neuroimmune diseases. The company’s research platform centers on the inhibition of the C1 complex, a key initiator of the classical complement pathway implicated in several rare and life-threatening disorders. By selectively targeting upstream complement activation, Annexon aims to prevent the aberrant immune-mediated damage that characterizes conditions such as Guillain-Barré syndrome (GBS) and autoimmune neuropathies.

At the core of Annexon’s pipeline is ANX005, a humanized monoclonal antibody directed against the C1q subcomponent, currently in Phase 2 clinical trials for acute GBS and chronic neurodegenerative indications.